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Hypothesis
IFN-g will induce upregulation of MHC-I,
MHC-II, and PD-L1 in a time-dependent
manner in the Yumm1.7-3.D8.B7 mouse
melanoma model.
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Figure 1. List of fluorescently conjugated antibodies
used for the experiment. Isotype-matched control
conjugated antibodies were added in separate
staining panels to act as controls.
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Figure 3. MHC-I and PD-L1 expression charts based
on mean fluorescent intensity (MFI).
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• The cells were stained in dark at 4℃ for
30 minutes. Afterwards, they were
washed with 200 ul of FACS buffer
• Cells were and resuspended in 400ul of
buffer and transferred FACS tubes
• Compensation single color controls were
used to correct fluorescence spillover and
prevent spectral overlap
Fluorescence-activated single cell sorting
(FACS) analysis
• The compensations were ran first on the
BD LSR FACS machine.
• Data were downloaded on our working
computers and analyzed using FlowJo to
generate plots and gates to determine
surface molecule expressions.
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Figure 4. MHC-II (vertical) and PD-L1 (horizontal) expression
dot chart.
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Methods
Thawing and Growing cells
• Frozen cells were thawed in a 37℃ water
bath.
• Thawed cells were washed and
transferred to a T75 flask
• Cells were grown in R10+BME media at
37oC/5% CO2
• After cell expansion, 500,000 cells were
seeded in 6 T-75 flasks
• Cells were treated with 0, 100, or 300
u/mL of recombinant mouse IFN-g for 24
or 72 hours
Harvesting and Staining cells
• After the incubation period, the cells were
harvested following standard cell splitting
protocol and transferred to a 96 well plate
to their assigned well
• The plate was centrifuged for 2 minutes at
2000 rpm and resuspended in 50 uL of 1x
Fc block master mix (0.5 Fc block, 49.5
FACS buffer per well) after decanting the
supernatant post-centrifugation
• The antibodies (Figure 1) and NIR dye
were centrifuged for 5 minutes and used
to make master mixed based on the
FACS panel designed prior the harvesting
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• T cell recognition of tumor-derived antigens
presented on major histocompatibility
complex (MHC) is critical for effective antitumor immune responses
• MHC class I (MHC-I) presents antigens to
CD8+ T cells, whereas MHC-II presents
antigens to CD4+ T cells
• T cells become activated upon recognition
of peptide-MHC along with co-stimulation
• Activation and T cell stimulation can also
upregulate the immune checkpoints CTLA4 and PD-1 and inhibit T cells
• Interferon-gamma (IFN-g) can induce
upregulation of MHC-I and PD-L1 (a ligand
for PD-1) on most tumors and MHC-II on a
minority of tumors including some
melanomas (1-3)
• MHC-II is usually expressed on antigen
presenting cells (APCs) like macrophages
and dendritic cells
• The role of MHC-II expression in melanoma
and how this affects that anti-tumor immune
responses is unclear
• We evaluated expression of MHC-I, MHCII, PD-L1, and the co-stimulatory molecule
CD80 on the Yumm1.7-3.D8.B7 melanoma
cell line engineered to express model tumor
antigens in the presence of absence of IFNg stimulatory conditions
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Results
• Yumm1.7-3.D8.B7 cells without IFN-g
stimulation expressed little to no MHC-I,
MHC-II, and PD-L1. (Figure 4 and 5)
• IFN-g induced upregulation of MHC-I and
PD-L1. (Figure 3, 4 and 5)
• MHC-I and PD-L1 expression dropped for
cells stimulated with 300 u/mL IFN-g for
72 hours compared to 100 u/mL treatment
group. (Figure 3)
• MHC-I expression was identified on more
than 90% of cells treated with IFN-g,
peaking near 99% at 300 u/mL of IFN-g.
(Figure 5)
• IFN-g induced upregulation of MHC-II, but
only on a subset of melanoma cells.
• The percent of MHC-II expressing tumor
cells increased from about 12.7% to
18.2% when increasing dosage of IFN-g
from 100 u/mL to 300 u/mL. (Figure 4)
• CD80 was constitutively expressed on
Yumm1.7-3.D8.B7. (Figure 6)
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Figure 5. MHC-I expression dot chart. Double
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•Consistent with our hypothesis, IFN-g
upregulated MHC-I and PD-L1
•IFN-g stimulation leads to MHC-II
expression by some tumor cells,
specifically less than 20% of all live
tumor cells
•Further research may be necessary to
identify whether the relationship is
significant enough to be taken into
consideration as a potential target to
tackle for cancer immunotherapy.
•It appears that the amount of time the
cells are exposed to IFN-g seems to
also play a role in the level of MHC-II
expression, where longer exposure time
would lead to more MHC-II expression.
•Perhaps, by upregulating IFN-g, we
could force solid tumors to express
more MHC-II than they usually do,
making them more susceptible to CD4+
T-cells.
•When comparing the 100 U/mL and
300 U/mL groups under the same
incubation times, there does not seem
to be any significant difference in MHCII expression, possibly due to saturation
of IFN-g
•Oversaturation of IFN-g stimulation
over a long period of time may down
regulate MHC-I and PD-L1 expression.
•Future research could be done to
check if there is an optimal
concentration for IFN-g for upregulating
surface molecule expression.
•While IFN-g is a dominant cytokine for
upregulating MHC and PD-L1
expression, other inflammatory signals
(such as IFN-a) can be explored upon to
examine whether they also regulate
surface molecule expression.
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